Initial Patterns of Care With Oral Targeted Therapies for Patients With Renal Cell Carcinoma
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell CancerJournal of Clinical Oncology, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sequential Sorafenib and Sunitinib for Renal Cell CarcinomaJournal of Urology, 2009
- Sequential therapy with sorafenib and sunitinib in renal cell carcinomaCancer, 2008
- Efficacy of Sunitinib and Sorafenib in Non–Clear Cell Renal Cell Carcinoma: Results From Expanded Access StudiesJournal of Clinical Oncology, 2008
- Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell CarcinomaClinical Cancer Research, 2007
- Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?Clinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib for the Treatment of Advanced Renal Cell CarcinomaClinical Cancer Research, 2006
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, 2000